Search alternatives:
"c values increased" » "c cases increased" (Expand Search), "c dalys increased" (Expand Search), "c also increased" (Expand Search), "ct values increased" (Expand Search), "i values increased" (Expand Search), "auc values increased" (Expand Search)
"_ values decrease" » "_ largest decrease" (Expand Search)
"_ larger decrease" » "_ marked decrease" (Expand Search), "_ large decrease" (Expand Search), "_ largest decrease" (Expand Search), "a large decrease" (Expand Search)
Showing 1 - 20 results of 176 for search '(("c values increased") OR ((("_ values decrease") OR ("_ larger decrease"))))*', query time: 0.45s Refine Results
  1. 1
    (A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)).

    (A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)). by Shakeel Ahmad Khan (13202394)

    Published 2025
    “…The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)).…”
    Save to List
    Saved in:
  2. 2
    Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24.

    Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART.

    Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model.

    Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24.

    Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24.

    Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Consolidated Standards of Reporting Trials flow diagram for participants in the trial.

    Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24.

    Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a.

    Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Participants with virologic suppression or failure at week 24.

    Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a.

    Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: